ClinicalTrials.gg
CompletedNCT00002132Updated Jun 24, 2005

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

An interventional study of Itraconazole and Fluconazole in Candidiasis, Esophageal and HIV Infections, sponsored by Janssen Pharmaceuticals. Completed at 18 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Janssen Pharmaceuticals (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fluconazole in Candidiasis — 1 open to participants now, 1 under way, none of them phase 3. Fluconazole · Candidiasis.

No phase
5 of 19
1 open now
Registered
1st of 19
by date
Lead sponsor
1 of 19
Janssen Pharmaceuticals

Among the 19 studies testing fluconazole in Candidiasis, this one is one of 5 with no phase, and was the 1st registered.

Candidiasis

132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.

Browse Candidiasis studies →

Open to participants now

1 of the 19 studies testing fluconazole in Candidiasis is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About fluconazole

Fluconazole: first FDA approval 1990 (DIFLUCAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluconazole in Candidiasis, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.

03

Conditions studied

  • Candidiasis, Esophageal
  • HIV Infections

Keywords

  • Itraconazole
  • Fluconazole
  • Acquired Immunodeficiency Syndrome
  • Candidiasis
  • Immunocompromised Host
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • Esophageal candidiasis.
  • Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture.
  • infection or other predisposing risk factor.
  • of at least 2 months.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • of the head or neck, if the treatment or disease will interfere with response assessment.
  • Evidence of systemic fungal infection.
  • Underlying clinical condition that would preclude study completion.
  • Judged to be unreliable in regard to following physician's directives.

Concurrent Medication:

Excluded:

  • Rifampin.
  • Rifabutin.
  • Phenobarbital.
  • Phenytoin.
  • Carbamazepine.
  • Terfenadine.
  • Astemizole.
  • H2 blockers.
  • Continual antacids.
  • Any drug (expanded access drugs are allowed).

Patients with the following prior conditions are excluded:

  • History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry.
  • History of to imidazole or azole compounds.

Prior Medication:

Excluded:

  • Other orally administered antifungal therapy within 3 days prior to study entry.
  • Any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

18 sites
  • Dr Eskild A Petersen
    Tucson, Arizona 85724, United States
  • Los Angeles County - USC Med Ctr
    Los Angeles, California 90033, United States
  • UCSD Med Ctr
    San Diego, California 92103, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Emory Univ School of Medicine
    Atlanta, Georgia 30303, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Johns Hopkins Univ School of Medicine
    Baltimore, Maryland 21205, United States
  • Wayne State Univ / Harper Hosp
    Detroit, Michigan 48201, United States
  • Univ of Missouri at Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • Infectious Diseases Association / Research Med Ctr
    Kansas City, Missouri 64132, United States
  • Montefiore Med Ctr
    Bronx, New York 10467, United States
  • Erie County Med Ctr
    Buffalo, New York 14215, United States
  • Dr Douglas Dieterich
    New York, New York 10016, United States
  • Univ of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Bowman Gray School of Medicine
    Winston Salem, North Carolina 27157, United States
  • Univ Hosps of Cleveland
    Cleveland, Ohio 44106, United States
  • Austin Infectious Disease Consultants
    Austin, Texas 78705, United States
  • Houston Veterans Administration Med Ctr
    Houston, Texas 77030, United States
07

References and documents

Publications

  • Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis. 1995;27(6):613-7. doi: 10.3109/00365549509047076. PubMed 8685642 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002132
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Fluconazole

Start the discussion